Nature Medicine, Published online: 01 July 2025; doi:10.1038/s41591-025-03832-2
A randomized phase 2a clinical trial of an AI-discovered drug and target combination for idiopathic pulmonary fibrosis shows safety and signs of efficacy, marking a concrete step forward in bringing AI-enabled drug discovery into the clinic.
